Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 33

1.

Glutaminase inhibitor CB-839 synergizes with carfilzomib in resistant multiple myeloma cells.

Thompson RM, Dytfeld D, Reyes L, Robinson RM, Smith B, Manevich Y, Jakubowiak A, Komarnicki M, Przybylowicz-Chalecka A, Szczepaniak T, Mitra AK, Van Ness BG, Luczak M, Dolloff NG.

Oncotarget. 2017 May 30;8(22):35863-35876. doi: 10.18632/oncotarget.16262.

2.

Phenotypic and functional characterization of a bortezomib-resistant multiple myeloma cell line by flow and mass cytometry.

Baughn LB, Sachs Z, Noble-Orcutt KE, Mitra A, Van Ness BG, Linden MA.

Leuk Lymphoma. 2017 Aug;58(8):1931-1940. doi: 10.1080/10428194.2016.1266621. Epub 2016 Dec 16.

3.

Fine-Mapping of 18q21.1 Locus Identifies Single Nucleotide Polymorphisms Associated with Nonsyndromic Cleft Lip with or without Cleft Palate.

Mitra AK, Stessman HA, Schaefer RJ, Wang W, Myers CL, Van Ness BG, Beiraghi S.

Front Genet. 2016 May 23;7:88. doi: 10.3389/fgene.2016.00088. eCollection 2016.

4.

PIAS1 Promotes Lymphomagenesis through MYC Upregulation.

Rabellino A, Melegari M, Tompkins VS, Chen W, Van Ness BG, Teruya-Feldstein J, Conacci-Sorrell M, Janz S, Scaglioni PP.

Cell Rep. 2016 Jun 7;15(10):2266-2278. doi: 10.1016/j.celrep.2016.05.015. Epub 2016 May 26.

5.

Utilization of translational bioinformatics to identify novel biomarkers of bortezomib resistance in multiple myeloma.

Fall DJ, Stessman H, Patel SS, Sachs Z, Van Ness BG, Baughn LB, Linden MA.

J Cancer. 2014 Sep 21;5(9):720-7. doi: 10.7150/jca.9864. eCollection 2014. Review.

6.

High-throughput drug screening identifies compounds and molecular strategies for targeting proteasome inhibitor-resistant multiple myeloma.

Stessman HA, Lulla A, Xia T, Mitra A, Harding T, Mansoor A, Myers CL, Van Ness BG, Dolloff NG.

Leukemia. 2014 Nov;28(11):2263-7. doi: 10.1038/leu.2014.214. Epub 2014 Jul 9. No abstract available.

PMID:
25005244
7.

Profiling bortezomib resistance identifies secondary therapies in a mouse myeloma model.

Stessman HA, Baughn LB, Sarver A, Xia T, Deshpande R, Mansoor A, Walsh SA, Sunderland JJ, Dolloff NG, Linden MA, Zhan F, Janz S, Myers CL, Van Ness BG.

Mol Cancer Ther. 2013 Jun;12(6):1140-50. doi: 10.1158/1535-7163.MCT-12-1151. Epub 2013 Mar 27.

8.

Targeted overexpression of an activated N-ras gene results in B-cell and plasma cell lymphoproliferation and cooperates with c-myc to induce fatal B-cell neoplasia.

Linden MA, Kirchhof N, Carlson CS, Van Ness BG.

Exp Hematol. 2012 Mar;40(3):216-27. doi: 10.1016/j.exphem.2011.11.006. Epub 2011 Nov 23.

9.

A transgenic mouse model of plasma cell malignancy shows phenotypic, cytogenetic, and gene expression heterogeneity similar to human multiple myeloma.

Boylan KL, Gosse MA, Staggs SE, Janz S, Grindle S, Kansas GS, Van Ness BG.

Cancer Res. 2007 May 1;67(9):4069-78.

13.
14.

Flip-PCR for DNA sequence motif inversion.

Schanke JT, Quam LM, Van Ness BG.

Biotechniques. 1994 Mar;16(3):414-6. No abstract available.

PMID:
8185911
15.

Enhancer mediated suppression of epsilon heavy-chain gene expression in a murine IgE-producing hybridoma.

Nelms K, Van Ness BG, Lynch RG, Mathur A.

Mol Immunol. 1991 Jun;28(6):599-606.

PMID:
1907351
16.

In vivo and in vitro regulation of IgE production in murine hybridomas.

Mathur A, Van Ness BG, Lynch RG.

J Immunol. 1990 Dec 1;145(11):3610-7.

PMID:
2147197
17.

Novel recombinations of the IG kappa-locus that result in allelic exclusion.

Feddersen RM, Martin DJ, Van Ness BG.

J Immunol. 1990 Jul 15;145(2):745-50.

PMID:
2114448
18.
20.

The frequency of multiple recombination events occurring at the human Ig kappa L chain locus.

Feddersen RM, Martin DJ, Van Ness BG.

J Immunol. 1990 Feb 1;144(3):1088-93.

PMID:
2104911
21.
22.

Single copy gene detection requiring minimal cell numbers.

Feddersen RM, Van Ness BG.

Biotechniques. 1989 Jan;7(1):44-9.

PMID:
2629832
23.

Glucose-dependent regulation of glucose transport activity, protein, and mRNA in primary cultures of rat brain glial cells.

Walker PS, Donovan JA, Van Ness BG, Fellows RE, Pessin JE.

J Biol Chem. 1988 Oct 25;263(30):15594-601.

24.
25.

Thymus-dependent in vivo suppression of IgE synthesis in a murine IgE-secreting hybridoma.

Mathur A, Kamat DM, Van Ness BG, Lynch RG.

J Immunol. 1987 Nov 1;139(9):2865-72.

PMID:
2959722
26.

In vitro splicing of kappa immunoglobulin precursor mRNA.

Lowery DE, Van Ness BG.

Mol Cell Biol. 1987 Apr;7(4):1346-51.

27.
28.
29.

Transcription of the unrearranged mouse C kappa locus: sequence of the initiation region and comparison of activity with a rearranged V kappa-C kappa gene.

Van Ness BG, Weigert M, Coleclough C, Mather EL, Kelley DE, Perry RP.

Cell. 1981 Dec;27(3 Pt 2):593-602.

PMID:
6101210
32.

Recognition of elongation factor 2 by diphtheria toxin is not solely defined by the presence of diphthamide.

Van Ness BG, Barrowclough B, Bodley JW.

FEBS Lett. 1980 Oct 20;120(1):4-6. No abstract available.

33.

Supplemental Content

Loading ...
Support Center